Upcoming Events
Log In
Pricing
Free Trial

Imaging Considerations after Gender-affirming Therapies, Dr. Justin Stowell (8-6-26)

HIDE
PrevNext

0:02

Hello, and welcome to Noon Conference hosted by Modality.

0:05

Noon Conference connects the global radiology community through free live

0:09

educational webinars that are accessible for all and is an opportunity to learn

0:12

alongside top radiologists from around the world.

0:16

Today, we are honored to welcome Dr.

0:17

Justin Stoll for a lecture entitled "Imaging Considerations After

0:20

Gender-Affirming Therapies." Dr.

0:22

Stoll completed his residency at the University of Missouri, Kansas City, and a

0:26

thoracic imaging fellowship at Massachusetts General Hospital, Harvard Medical

0:30

School.

0:31

Since joining the Mayo Clinic in 2019, he has served as lead radiologist for the

0:35

Florida Lung Cancer Screening Program.

0:38

His clinical interests include interstitial lung disease, lung cancer screening and

0:41

therapeutics, and developmental lung disease.

0:44

He also advocates for and educates about the healthcare needs of the transgender

0:48

community, especially in the field of radiology.

0:51

At the end of the lecture, please join him in a Q&A session where he will address

0:54

questions you may have on today's topic.

0:56

Please remember to use the Q&A feature to submit your questions so we can get to as

1:00

many as we can before our time is up.

1:02

With that, we're ready to begin today's lecture. Dr.

1:04

Stoll, please take it from here.

1:07

All right. We'll go ahead and get started.

1:11

So

1:12

this discussion is about imaging considerations for transgender patients,

1:16

which are a unique population that we care for in radiology.

1:21

So today I want to just emphasize basically all the things that we should be

1:24

considering from an imaging perspective in caring for these patients.

1:29

Okay, so I have no relevant disclosures to this talk other

1:33

than-- But I do want to say that I am cisgender, meaning that my gender identity

1:37

aligns with the sex that was assigned to me at birth.

1:40

And so

1:41

during this talk, I'll discuss transgender patients'

1:44

experiences in the radiology encounter, and I want to

1:49

just emphasize that it's through the lens of a cisgender individual and from what

1:53

I've heard from the community, from patients' feedback, also what

1:57

I've studied from the literature, and then also what I've heard among the

2:00

community, for example. So I want to just disclose that this is

2:04

potentially a slight bias through a cisgender lens, but I'll

2:08

try to be as objective moving forward with that and emphasize the community

2:12

aspect of this.

2:16

So first I'll do some introduction with terminology and epidemiology and

2:20

care standards. We actually have care standards for transgender health, kind

2:24

of dominated and

2:27

organized by the World Professional Association for Transgender Health, or

2:31

WPATH.

2:32

And so I consider them the WHO for transgender

2:36

healthcare. It's a great organization that

2:39

really looks at the data and the standards and

2:42

tries to make it--

2:45

or has developed standards of care.

2:47

And then I'll really emphasize the new anatomy related to gender surgery,

2:52

and how the imaging can be used in the diagnosis and management of any

2:55

complications of that.

2:57

Also, same thing with hormones and potential changes of hormone therapies and how

3:00

that might affect our imaging. And then finally, I'll end the talk with discussions

3:04

about how we can make our departments more affirming and welcoming for these

3:08

patients, whether it's processes and procedures, or at least just start the

3:11

discussion of ways that we might be able to improve the encounter.

3:15

So as an introduction and getting everyone on the same page,

3:19

the gender identity-- So we're talking about gender identities today when we speak

3:22

of transgender patients. And a transgender person has a gender

3:26

identity or their inner sense or experience of gender that

3:30

differs from the sex that was assigned to them at birth, which

3:34

is usually based on external genitalia.

3:38

And not often is a chromosomal analysis even conducted, or maybe there's some

3:42

prenatal ultrasound that's mainly focused on external genitalia.

3:45

However,

3:47

the body or the sex organs develop at a

3:51

different time than our gender identity, and it's understood that gender identity

3:55

is more of an inner experience, and it probably develops more close to around

3:59

the age of three, maybe four, where people start to recognize, I'm

4:03

a boy or she's a girl, for example. And so there's a

4:06

discordance with when we develop physically and when we

4:10

develop intellectually and internally.

4:14

A trans man, for the purpose of this discussion, will be

4:18

someone whose gender identity is male or

4:21

masculine and was assigned female sex at birth.

4:25

Vice versa for trans woman, someone who was assigned male sex at birth but

4:28

identifies as feminine or a woman.

4:32

Gender diverse is kind of an inclusive category for folks that don't

4:36

identify on a binary spectrum. So they may be somewhere in between, neither,

4:40

or both. I'll use the term trans masculine, trans feminine to

4:45

honor that spectrum of gender identity,

4:48

rather than being completely binary.

4:50

And then gender dysphoria is the actual diagnostic

4:54

term from the DSM-5 related to psychological or social

4:58

distress caused by this gender incongruence with

5:02

the sex assigned at birth and gender identity.

5:05

I want to emphasize that transgender and gender identity

5:09

are not diagnoses. They're not something we treat. We don't treat transgender.

5:13

We treat gender dysphoria because of this incongruence and how

5:18

it's affecting the patient. And so we have different treatments, which I'll

5:21

discuss, that we can apply to help alleviate gender dysphoria.

5:25

Sexual orientation is completely different than gender identity, but it's often

5:29

included among that LGBTQ rainbow, kind of that

5:33

umbrella. But sexual orientation is one's individual preference or

5:37

desire for sexual intimacy with others, whether it's a cisgender person

5:41

or a transgender person. So

5:43

sexual orientation can be anything among the transgender community.

5:47

And then, as I mentioned, the gender-affirming therapies, whether it's

5:50

psychological, social transition, hormones, or potentially surgery.

5:55

Those gender-affirming therapies are listed here.

5:57

We have feminizing gender-affirming therapies and masculinizing therapies.

6:01

Not all patients will require all of these to feel affirmed in

6:05

their selves. And so

6:07

Just understand that not every person, just because they identify as transgender,

6:10

may require the full spectrum of all these treatments.

6:13

Some may only need a social transition or psychological support,

6:18

and may not even require hormones or surgery.

6:21

So that's something I wanted to emphasize here, but

6:25

these are the options that are available for these patients.

6:29

There was a large survey done in the United States that was published in

6:33

2015, and this was over 50,000 respondents.

6:36

But this is just showing you that the desire for these various gender-affirming

6:40

therapies can be highly variable, and you can see that

6:44

some things are highly desired. A lot of patients have it or want it

6:48

someday.

6:50

For example, some of the more advanced surgical options, a lot of patients don't

6:54

desire those or may not necessarily desire those.

6:58

This is data from

7:01

US insurance claims, and we did have an expanding

7:05

health insurance coverage for transgender care.

7:08

There was an increase in demand of gender-affirming care in the United States.

7:11

But despite all this, there's still high rates of healthcare avoidance among this

7:15

population, and this is just data from this study that looked at US

7:19

claims up to 2020, and it shows that there was an overall

7:23

increase in demand in utilization of gender-affirming surgeries.

7:27

And you can see how that's broken down, whether it's breast or chest surgery versus

7:30

a genital surgery or some other cosmetic surgery there.

7:34

And if you look at the age category of the patients that are undergoing surgery,

7:37

you can see that often a breast or a chest surgery is the earliest type of

7:41

surgery they might pursue, followed by the genital surgeries are usually at

7:45

a later age. And that's probably related to when breast tissue starts

7:49

to develop, for example, in a transmasculine person, they may desire to have

7:53

top surgery to remove that, as that's the part that's causing them so much

7:57

dysphoria. And so that may be applied earlier,

8:01

or it's just easier to access some of those types of surgeries, or maybe that's all

8:04

they require, so they start early, and that's all they need,

8:07

and then some of the other surgeries come later.

8:10

So epidemiologically speaking, I like to get a snapshot of where are the

8:14

patients and how many patients are we talking about.

8:16

And so there's not a

8:19

real good, robust collection of this type of

8:23

data. There is no question on the US

8:27

Census to collect this data, but we do have some large surveys that were conducted

8:30

in the United States. So you can see that worldwide, it's estimated about 25

8:34

million trans persons are across the globe.

8:37

Probably an underestimation, to be honest.

8:40

In the US, it's estimated at about 0.8% of US adults,

8:43

or if you do the numbers, about 2 million.

8:46

And you can see how that's broken down by gender identity here.

8:49

Youth comprise about an estimation of 3.3% of youth in the

8:52

United States. And you can see from this map

8:56

where those patients reside or where those people are residing.

8:58

And so I was surprised to see the distribution that the highest

9:02

concentration is in

9:04

some of the highest concentrations in the South.

9:07

Here's an

9:09

update of the Transgender Health Survey that was published in 2022, again,

9:13

over 92,000 respondents, again, showing that we have trans

9:17

patients living all across the United States in

9:21

outlying territories, and again, the highest concentration in the South.

9:26

Canada does include this data point on their census, and so this is

9:30

Canadian census data showing the relative breakdown of

9:33

transgender folks in that

9:36

population in Canada.

9:38

And then other countries that collect this data, again, Belgium, New

9:41

Zealand. The image on the right is data from

9:45

one transgender health clinic in the Netherlands that's been serving as a

9:49

central core clinic for transgender health for many years,

9:53

and you can see the increasing demand,

9:56

especially among adults and even youth and adolescents.

9:59

So we see growing number of people that have been

10:03

identifying as transgender and coming to care.

10:08

So these gender-affirming therapies, what are the effects of them and what are the

10:11

outcomes? And so across many, many publications, we see

10:15

continued results showing that patients who are given access to

10:19

hormones or surgery for gender-affirming therapies result in a much more

10:22

satisfied life, and are much more satisfied with

10:26

themselves. Very few express regret or undergo regret.

10:30

And so you can see that from these data, again, this comes back over and over again

10:34

in the literature. So it shows that gender-affirming therapies are

10:38

evidence-based and effective.

10:41

I include this slide only because I think it's important for radiologists to know

10:44

that these patients do, unfortunately, as a population, suffer from

10:48

higher rates of violence inflicted upon them, and you can see how that's broken

10:52

down here. And so unfortunately, this population may be subject to

10:56

violence, and that might be reflected in some of the things we see on our imaging.

10:59

So keep that in mind that you might see non-accidental trauma in the

11:03

adult, for example, in some of these patients.

11:05

So keep a lookout when you're imaging these patients.

11:09

This is just data that shows around 65% across a

11:12

meta-analysis of the literature shows that a rate of around

11:16

65% have expressed some form of violence.

11:21

So how does radiology fit into all this?

11:23

So we know that medical imaging is prolific.

11:25

It's used by almost every other subspecialty department.

11:28

So transgender patients are no different in that they will probably encounter

11:32

imaging or have an imaging encounter at some point through their journey in

11:36

healthcare. And again, that can be from general medical conditions, coming in for

11:40

anything. Here's an example of appendicitis in a trans woman who had undergone

11:43

vaginoplasty.

11:45

Or they could be coming specifically to evaluate

11:48

problems related or physiological effects of their

11:52

gender-affirming therapy. So nonetheless, radiology is central to this care, and so

11:55

that's why we're here today to discuss it.

11:58

So I got interested in this study, and I wanted to really focus on

12:03

how does the transgender patient have a

12:07

radiology encounter, and what are the steps, the touch points that they might

12:11

have access to, and how do we interact with them?

12:14

And so I did a large survey back in 2020 already,

12:18

believe it or not, or before that. And so it was published in 2020, but

12:22

this is some data. So I'll present some of that data from that survey, just so you

12:25

have an idea of how these patients encounter our department specifically.

12:28

It includes data from over 500 respondents

12:32

across the United States, so pretty robust collection of patients and their

12:36

experiences in radiology.

12:38

So what we found was 71% had at least one negative experience when

12:42

coming to radiology departments, and half felt that their gender identity was the

12:46

reason for that discomfort in the department.

12:49

A quarter experienced negative interactions with imaging staff.

12:52

And so,

12:54

patient-facing individuals might have been the reason for these negative

12:57

encounters. A third had to instruct the staff about transgender people to

13:01

receive appropriate care. That is the same as for a

13:05

large

13:06

primary care survey that was done, a separate one.

13:10

So about a third had to

13:12

explain what transgender people were to the providers to get

13:16

care. And then within radiology, again, about a third said that

13:19

the staff seemed uncomfortable caring for them.

13:21

And so, those are things that we could work on.

13:24

So that all speaks to me as education of our providers, and so again, why we're

13:28

here. These are quotes from folks who participated in our

13:32

survey. I wanted the voice of the trans patient to come through so we can

13:36

really get a granular understanding of what's happening.

13:38

So I'll let you just read those thought bubbles, but those are actual quotes.

13:41

But you can see that again,

13:44

this data point was 16.7% were made to feel unwelcome or

13:47

unsafe. And, I think that's unacceptable for any of our patients, whether you're

13:51

trans or cisgender. I think that should be a 0% for anyone.

13:55

And so there's some work we can do in radiology.

14:00

I wanted to know, were these encounters through the emergency department,

14:03

outpatient, inpatient? Maybe the emergency department is a stressful

14:07

setting anyway, and maybe that had a heightened

14:11

negative encounter. But actually, most of the respondents had had outpatient

14:15

imaging encounters, so relatively calm, cool, controlled

14:18

environments. And unfortunately, they were still having these experiences.

14:22

There was really no association with the population or where

14:26

the patient was located, whether it was urban, suburban, or rural imaging

14:30

departments,

14:31

whether they had a positive or negative experience.

14:33

So it told me across the board, radiology has some work to do to improve.

14:38

So I'm going to do this a little different than the last time that I presented for

14:42

Mediality and MRI online. I'm going to do a case-based approach so that it

14:46

really shows you and highlights the patient experience.

14:49

These are real patient cases that I've anonymized, but these are ones that

14:53

actual trans patients in their encounters in radiology.

14:56

So first, we'll start with Jack. He's a transgender man, meaning he was assigned

14:59

female sex at birth, identifies as a man, is sitting in the waiting room for a

15:03

breast imaging center. The staff from the front desk calls out

15:06

Jessica, which is Jack's legal name, that's on his documentation still,

15:10

and he responds embarrassingly and walks up to the front desk.

15:14

And again, his expressed gender for all the other people in the waiting room is

15:18

very different than you would expect someone named Jessica.

15:21

So Jack, other patients in the waiting room, the staff person,

15:24

created an uncomfortable scenario.

15:28

And for Jack, immediately, this breast imaging center is not a safe

15:32

space, right? The limelight's on him.

15:35

So with regards to those terms, that's why terminology is so much

15:38

emphasized among this population and among education here, is that when we

15:42

misgender someone or refer to the wrong gender or

15:46

pronoun, for example,

15:48

that can really affect these patients.

15:51

And it's an exposure, it creates an unsafe space for them.

15:55

And it's inaccurate. So it's something that we should be more accurate about

15:58

because these are important things as we encounter folks.

16:02

Using a dead name, which is what occurred in this scenario, is the patient's name

16:06

that they no longer

16:09

identify with. Unfortunately, not everyone can undergo legal name changes or

16:13

hasn't

16:14

done that step yet, so it might be different on our medical documentation.

16:17

You just have to be aware of that and sensitive to that.

16:21

Again, I mentioned pronouns and using the right pronouns.

16:24

And, this is sometimes difficult

16:27

for a provider to use the appropriate pronoun, but if you

16:31

mix up, if you use the wrong one, if you misgender, it's not a failure

16:35

on your part. Just quickly apologize, acknowledge the error, and move

16:39

on. And that's actually been shown,

16:41

numerous studies have suggested that that's the best way to do this.

16:44

Don't belabor the mistake. Just be sincere and say, "Oh my gosh,

16:48

I used the wrong pronoun. My apologies, I'll do better.

16:51

And let me know if I make a mistake."

16:54

Ways that we can inform ourselves.

16:56

The EMRs are now available. Patients can

17:00

self-report their gender identity.

17:02

And so look for that sort of thing, or look for other clues, for example,

17:06

including pronouns in name tags and in

17:10

signature lines.

17:12

Another way is just, "How would you like to be addressed today?" Or, "How can I

17:15

best address you?" That's one way to get people, maybe the patient, to just

17:19

disclose that.

17:20

Again, EMRs have this availability, so if your site has that, make sure

17:24

that it's

17:26

available to patients.

17:28

And in our survey, we showed that 25% noted that of

17:32

those discriminatory or non-affirming interactions with radiology

17:36

staff, pronoun use was a highly cited reason for that.

17:38

So again, all part of the education we're providing here, and you can see how

17:42

that played out in our survey. I wanted to know in the

17:46

radiology report, so many patients are reading their reports now.

17:49

How

17:50

often are people misgendered in their reports?

17:52

And one quarter specifically said in the radiology report, they were misgendered.

17:56

So when you're providing a history, you may not even need to

18:00

include the gender. Just say 74-year-old with chest pain, for

18:04

example.

18:06

All right. So other ways, as providers, you can use these pronoun pins.

18:10

My institution allows us to do branded

18:14

pronoun pins if you want to wear them, and it's just a subtle indicator to the

18:18

patient that you may be someone they can open up to, and that

18:22

you maybe are affirming for them in this encounter.

18:25

All sorts of different ways you can do that in a subtle, quiet way without having

18:29

to just ask all the time. All right, next case.

18:33

Robert, a trans man with family history of breast cancer, had top surgery or

18:36

removal of breast tissue to become kind of more masculinized

18:40

chest

18:41

in the last decade. He was counseled on his need for breast cancer screening.

18:45

He did not feel comfortable about the concept of mammograms, and actually was

18:48

dysphoric, but he did agree to go and have a chest wall exam and an

18:52

ultrasound to begin.

18:54

So he was sent to the breast imaging center with an order that specifically said no

18:57

mammogram.

18:59

When he arrives, these are the things that all of our patients are seeing, and this

19:03

came back in our survey. So, they're looking at the signage.

19:06

They're trying to determine, "Is this a safe space for me to be and receive care?"

19:10

And so especially breast imaging centers, they can be heavily gendered, and

19:14

so I would encourage you to look through your breast imaging centers, all of your

19:17

facilities, to see are there subtle signs?

19:20

Are there signs out there, or is it heavily gendered unnecessarily?

19:23

For example, in this case, women's breast imaging area specifically

19:27

was advertising toward women, but we know that all sorts of people use breast

19:31

imaging, including cisgender men.

19:32

And so, that's just one small thing that we can do to really improve

19:36

outcomes for these patients.

19:39

And here's one that the mammogram room was pink and specifically said women

19:42

only, which is kind of interesting if you think of it even in the terms

19:46

of a cisgender man.

19:49

So chest masculinization surgery, which this patient had undergone, is removal

19:53

of breast tissue to create a more masculinized appearance of the chest.

19:57

It is different than oncologic mastectomy, and I think that's important for the

20:00

radiologist to know in that they do often a double incision,

20:05

modified mastectomy, where they remove the inframammary fold.

20:07

That's why you have these transverse incision lines.

20:10

And then they will do a free nipple graft using areolar tissue.

20:14

So they will position it where the plastic surgeons will position this

20:17

appropriate nipple position.

20:20

Their goal is to create a masculinized pectoral swoop to the chest, right?

20:24

So they

20:25

do leave behind some

20:28

fibroglandular tissue, and so that's important and has implications for breast

20:31

cancer risk and

20:33

all of that moving forward. And so that's something for us to know.

20:36

Here's an example on a CT where they thought that the patient might have had an

20:39

infection after top surgery, but this just was expected postoperative

20:43

inflammation and changes in the tissues within two weeks of the surgery.

20:48

You may see drains on the imaging immediately post-op.

20:51

Again, this is just to prevent hematoma formation or seromas, and so

20:55

some patients may require drains.

20:58

So what are breast cancer screening recommendations?

21:00

Remember, this patient was sent to the imaging facility for this indication,

21:04

and so they agreed with a chest wall exam and ultrasound to begin.

21:08

But we used to have varying recommendations for this

21:12

several years ago, and there were different centers of excellence that had the

21:15

recommendations. Mostly similar, but can be different.

21:18

But the American College of Radiology actually came together and

21:22

published in 2021 guidelines for this that are the most comprehensive,

21:26

most evidence-based, and so this is what I would refer you to

21:29

for your transgender breast cancer screening recommendations.

21:34

And for trans men who have had top surgery, we don't have enough data

21:38

to support or advocate for breast cancer screening, so it's

21:42

kind of a gray box. We really don't know the best way to image these patients.

21:45

We also don't know, are these patients willing to come for breast cancer

21:49

screening, right? Either before or after top surgery.

21:52

And in my experience in communicating with the trans community, most are

21:56

not. So we don't have good data to support for or against breast cancer

21:59

screening in this setting.

22:01

What our survey did show is that certain imaging exams can

22:05

produce discomfort for these patients, and so we should be more

22:08

sensitive to the trans community who might have to undergo certain exams.

22:12

One of which, and you can see emotional, psychological, and physical

22:16

discomfort that we collected. And when we asked the question in the survey, we

22:20

said, "This is physical or emotional psychological discomfort that is above and

22:23

beyond that which you would expect or were forewarned

22:27

prior to undergoing the procedure." Not surprisingly, the

22:31

hands-on imaging modalities like image and guided procedures,

22:35

ultrasounds, and mammograms, produced the most physical

22:38

discomfort.

22:40

Similarly, emotional psychological discomfort on the other graph.

22:44

And so if you think about this patient going in for-- They said no mammogram, but

22:48

he was going to do an ultrasound.

22:50

You might provide some

22:54

guidance ahead of time to let them know, "Hey, this could potentially be physically

22:58

or emotionally traumatizing." What worries me is the emotional

23:02

psychological graph. You'll notice the Y-axis is completely different than the

23:06

physical graph. So across all modalities, the patients in our survey were

23:09

reporting higher levels of emotional psychological discomfort

23:13

than that was expected or forewarned for these procedures.

23:17

And then these hands-off modalities shot up.

23:20

About one in five patients reported emotional psychological trauma from

23:23

hands-off sort of imaging modalities.

23:25

So keep that in mind when patients are coming to your center and provide

23:29

anticipatory guidance. I think a lot of these, like the MRI,

23:33

X-ray, CT, might have been based on the feedback, the verbal feedback that we got

23:36

in the survey was from things the patient was hearing while the exam was going on

23:40

from technologists, et cetera. So,

23:43

keep that in mind.

23:45

Here are two examples of mammograms in patients who have had top surgery, and so

23:48

you can see how difficult it is to perform these.

23:50

And so that's why it's probably not the best modality for breast

23:55

cancer screening in this patient population, because one, the patients probably

23:58

don't want to undergo it. Two, it's probably very difficult to achieve a

24:01

high-quality imaging exam. And you can see on the right here, there's a breast

24:05

cancer off screen And so the patient was having a palpable abnormality,

24:09

but you can barely see that breast cancer in this case.

24:12

So what is the risk of breast cancer in trans men?

24:15

We have many case reports. We don't have a comprehensive analysis

24:19

of this. There's one population-based data set coming out of that clinic

24:23

in the Netherlands, which I'll present here.

24:25

But we do know that on average, trans guys who develop

24:29

breast cancer or have the diagnosis, the median age is 41, which is

24:32

younger than expected for most cisgender women.

24:37

Most present in the setting of a diagnostic abnormality rather than a screening,

24:41

and six

24:43

that we know of

24:45

are after chest masculinization or potentially incidental cancers found on

24:49

mastectomy specimen after top surgery.

24:52

So here's just an example of one unfortunate patient who developed a breast cancer

24:56

right along his top surgery incision.

24:59

From that Netherlands cohort that I discussed, they did find that trans men do have

25:03

a higher risk compared to cis men, which would make sense, especially if

25:07

they had not undergone top surgery.

25:10

But they do, especially after top surgery, have a decreased risk compared to

25:13

cisgender women. And again, this is not a risk-reduction mastectomy.

25:17

This is a gender-affirming mastectomy, so there is

25:21

tissue left behind, and there may still be some risk there.

25:25

So let's continue with Robert. He went back to his primary care distressed and said

25:29

he was forced to undergo a mammogram at that visit.

25:31

Now he refuses to have any kind of screening.

25:34

So we just lost a patient because of that encounter.

25:36

So radiology has a significant influence on the care provided to these

25:40

patients, and we should continue to work with our primary care providers and

25:43

referring clinicians to help maximize these experiences for everyone.

25:48

So all these ways we could have done better in this encounter are listed here.

25:51

Again, respect patient autonomy, understand the utility of the imaging.

25:55

Mammography might not have been best for him.

25:58

Again, really seek feedback and provide that anticipatory guidance.

26:03

So next case, Jasmine is a 53-year-old trans woman, feminizing hormones for

26:07

15 years, breast augmentation, vaginoplasty,

26:11

and presented for routine preventative care. She has a mother with breast cancer.

26:14

She's a criminal defense lawyer, history of smoking, and interested in

26:18

pursuing facial feminization. So lots of things to talk about with this

26:22

preventative visit and this patient.

26:25

So again, back to the breast cancer screening.

26:27

We'll jump right to the ACR guidelines because we have that.

26:29

So trans feminine persons at age 40 or older who have

26:33

hormone use greater than five years are considered average risk,

26:37

and so they should undergo annual breast cancer screening.

26:41

And so there's a bit more data behind this, and so we have a pretty strong

26:44

recommendation there.

26:46

And I'll let you guys go ahead and scan this, and this will take you right to the

26:50

ACR recommendations. Again, these are based on expert

26:53

consensus and retrospective cohort studies.

26:55

We don't have prospective data in either trans masculine or trans

26:59

feminine breast cancer screening recommendations.

27:02

I think there are some sites working on this.

27:04

Again, that's going to take a long time to get that data.

27:06

But we do know from many different surveys and different studies that there

27:10

are lower rates of breast cancer screening and adherence among trans

27:14

communities compared to cisgender communities.

27:16

So, some work we need to do to encourage breast cancer

27:20

screening when appropriate.

27:23

So for trans women, we know that breast tissue does develop under

27:27

the influence of feminizing hormones, tends to follow a similar trajectory to

27:31

that of pubertal cisgender women, for example.

27:34

So,

27:35

60% get heterogeneously dense or extremely dense tissue on mammography,

27:39

which we know those are the two independent risk factors for breast cancer.

27:43

Histologically, the tissue is different than, for example,

27:47

gynecomastia. It's actually functional tissue where they develop terminal

27:51

ductal lobule units, and so they can be at risk for the same sort

27:55

of things that cisgender women may be at risk for.

27:58

There are case reports of successful breastfeeding as well, and so again, this is

28:01

functional tissue. Here is an example of histologically proving

28:05

pseudolactational change within a TDLU of a trans

28:09

woman. So I refer to it as feminized breast tissue on my reports

28:13

rather than gynecomastia because it is not the same histologically as

28:16

gynecomastia.

28:18

Here's just active tissue on a bone scan, and again, showing you that this is

28:21

physiologically active tissue. Here's an example of a fiber adenoma

28:25

that was detected, and again, look how dense that tissue is on the

28:29

mammogram. So keep that in mind.

28:32

Breast cancer, what do we know about this?

28:34

So there are 26 reported cases in the literature.

28:37

Average age is 51, again, younger than we would expect for cisgender women.

28:41

And most present, again, outside of the context of screening.

28:45

There were just a few associated with implants.

28:48

And this is one example from our institution where a patient had developed

28:52

progressive swelling of one of the breasts after being on hormone therapy for a few

28:55

years, and it was determined to be a breast cancer.

28:58

She had a genetic predisposition to this that was not known prior

29:02

to starting the hormone therapies.

29:04

And from that cohort in the Netherlands, again, it's a large cohort, so this is the

29:08

best data we have, retrospective.

29:11

There is a 47-fold higher risk among trans women compared to cisgender

29:15

men. And I'm going to pause there just because

29:20

putting that into perspective, cisgender men have a less than

29:23

1%

29:25

chance of developing a breast cancer, very low.

29:28

So 47-fold higher than less than 1% is still pretty low

29:32

overall,

29:33

but side by side, it is higher.

29:36

And then it is three times lower risk compared to cis women.

29:38

So trans women probably fall in between there within the risk

29:42

category. So that's why we have recommendations.

29:46

Some women will elect to undergo augmentation because most don't

29:50

achieve Tanner Stage 5 development, so may undergo silicone or

29:54

saline implants. And so that's important when we come for breast cancer

29:58

screening, that we inform the patients they may need to do implant displaced views.

30:02

You can see in this case, they were able to see the microcalcifications much better

30:05

after doing implant displaced views.

30:08

Silicone injections, injection of free liquid silicone into the

30:12

tissues for augmentation. This is illegal in the United States.

30:16

Unfortunately, this population may be subject to this, whether it's lack of

30:20

access to other types of

30:22

augmentation or that they're actually exploited and targeted in

30:26

social settings, for example, to receive this.

30:28

So it's high risk in that it disfigures the breast, makes it

30:33

very difficult to do

30:35

screening and finding cancers within all that.

30:37

It can

30:38

lead to necrosis and cyst formation, and then it can be taken up in

30:42

the lymphatics and brought to the lungs, for example, and it can be fatal.

30:45

In this case, unfortunately, this trans woman had received silicone injections

30:49

in another country, was flying back to the United States and developed shortness of

30:53

breath and fevers. This was in the pre-COVID era, so

30:57

these were silicone emboli that ultimately led to her demise.

31:00

And you can see the histologic specimens from her lungs showing silicone

31:04

globules within the

31:07

lungs. So continuing with this patient, other forms of preventative care

31:11

we could consider.

31:12

I'm a chest radiologist, so I'm really interested in her smoking history here.

31:16

And so what do we know about cancers in transgender folks?

31:19

So lung cancer is still the most common cancer among all transgender

31:23

folks. So keep that in mind, and that we tend to kind of hone in on

31:27

all these other gender type cancers.

31:28

But lung cancer, unfortunately, is still the highest

31:32

percentage of cancers among this population. You can see the rest broken down here.

31:35

This is based off of US data from the SEER

31:41

database.

31:43

This is UK data, again, showing GI and lung cancers are the

31:47

highest neoplasms that resulted in death in the UK.

31:51

Again, just keep that in mind that lung cancer is prevalent as well as colorectal

31:55

cancer.

31:56

So lung cancer screening, what do we know?

31:58

That this population, although they may be more inclined to smoke than cisgender

32:01

folks for various reasons as listed here, they have these unique

32:05

barriers to getting the preventative screenings that they may need, and that

32:09

includes lung cancer screening. So we did a study where we looked at US

32:12

survey data

32:14

of lung cancer screening utilization and compared transgender versus cisgender,

32:18

and we saw that although the respondents showed a similar

32:22

rate of eligibility, so both cisgender and

32:26

transgender folks in this survey showed similar eligibility rates.

32:30

Of course, utilization was much lower among the transgender community.

32:34

And

32:35

there are various ways that we could think about why that is.

32:38

So

32:39

something to keep in mind.

32:41

Not only just higher rates of tobacco consumption, alcohol use, but also may be at

32:45

risk for certain types of malignancies related to co-infection, like with

32:49

HIV or HPV. So keep those in mind as we're caring

32:53

for this patient population.

32:55

And there is a large study that showed transgender folks are often

32:59

diagnosed at a younger age than cisgender people.

33:02

Their primary site cancers, the rates, the

33:06

proportional incidence rates are higher

33:09

than cisgender people, especially for viral induced cancers.

33:13

So like anal cancer, Kaposi sarcoma, for example, the

33:17

squamous cell type cancers that people can get.

33:21

What is the risk of thromboembolic disease? So this patient is on hormone therapy.

33:25

So we know that there is an increased risk of venous thromboembolism and

33:29

complications related to feminizing hormones,

33:32

especially if

33:34

oral ethinyl estradiol, which is the same as used in birth control, and

33:38

conjugated equine estrogens. Again, these are synthetic estrogens.

33:42

They are not considered the standard of care for gender affirming therapy.

33:45

We use bioequivalent beta estradiol, and that is determined by the

33:49

WPATH organization, that there's more data that shows the risk of

33:52

thromboembolic phenomenon is much lower if you're using the bioequivalent forms,

33:56

and so that's considered the standard of care.

33:59

Supraphysiologic dosing. So these patients on hormone therapy should be getting

34:03

monitored for their estrogen levels.

34:05

And most patients, you know that I think this not when you're

34:09

supraphysiologic, you're going to be higher risk for thromboembolic disease.

34:13

All of the case examples I have are in patients who were very

34:17

supraphysiologic on their dosing, so they weren't getting monitored.

34:20

Again, smoking and some of those other causes.

34:24

This is a large data set from the United States based out of the Kaiser Health

34:27

Institute, again, emphasizing that we do know that there is an increased risk of

34:31

thromboembolic phenomenon or DVT/PE in this

34:35

group, especially the longer someone is on therapy.

34:39

So prostate cancer, again, this is a preventative visit.

34:42

What's this patient's risk for prostate cancer?

34:45

The prostate is not removed during vaginoplasty, which I'll discuss.

34:49

It does atrophy under feminizing hormones, but it's still biologically active.

34:53

Their PSA is not as reliable, but you can trend it.

34:56

It won't meet the same thresholds that a cisgender male

35:00

PSA might before you start getting concerned, but just that's why PSA is

35:04

trended in this population.

35:06

We do know that prostate cancers have been reported.

35:10

It's estimated that the incidence is probably lower than cisgender men,

35:13

mainly because the gland overall is suppressed, but again, it doesn't go to zero.

35:18

And then these patients might not be getting screening, and the reported cases have

35:22

been highly aggressive or highly advanced at the time of the report.

35:26

So still a lot to know about prostate cancer in this population.

35:30

I do have several examples of advanced prostate cancer that's bladder invasive

35:34

within transgender women. You can see it's already

35:36

metastasized to the spine in this case.

35:40

Here's another one with bladder invasive cancer shown on MRI, and then you can see

35:44

early lymph node metastases on the CT.

35:48

So osteoporosis, the effects of hormones on bone health are

35:52

important, and there's quite a bit of data in this.

35:55

And to the point where the ICE, the International Society of Clinical

35:58

Densitometry, has made official position statements because of the amount of data

36:02

available on bone density related to hormone therapy.

36:05

So I would refer you to this table. This is how we should be doing this.

36:08

Your technologist might ask, should we compare to male or female

36:12

nomograms? And this document shares all of those

36:16

information

36:17

Here are just two examples of women who had to come off of their estrogen hormones

36:21

or feminizing hormones for various reasons,

36:24

and they ended up developing osteoporosis, and one developed spinal compression

36:28

fractures from insufficiency.

36:31

Another thing about prevention in this patient is HIV infection and the risks

36:35

that might be present. And so

36:37

trans women have a higher prevalence of HIV infection, and

36:41

we mentioned that in the cancer discussion as well.

36:44

It is a higher incidence compared to cisgender folks, and you can see the breakdown

36:48

also affects different ethnicities, and so that's important to keep in mind

36:53

the rates of HIV infection that might be occurring.

36:55

And whether or not this group is well-controlled in their HIV or maybe not

36:59

getting good control. And again, even in the South, this is a higher

37:03

burden that's been shown by the CDC

37:05

data. If you look at rates of HIV diagnoses, this

37:10

includes cisgender folks, it can be variable.

37:12

So if you're a teleradiologist, where you're reading this patient's case

37:16

from or where this patient resides may affect their-- they may be

37:20

relatively more at risk for these different things based on the state in which they

37:24

live.

37:25

Keep in mind that if someone is uncontrolled with HIV, they may develop

37:28

opportunistic infections, so something to kind of keep in mind while you're reading

37:32

these cases. This is pneumocystis pneumonia in this

37:35

case.

37:37

So facial feminization, the patient's interested in facial feminization.

37:40

So neuroimaging, we are often centered in the middle of

37:44

neuroimaging, or you may just be reading someone's head CT, for example, who has

37:48

undergone facial feminization surgery.

37:50

The goal is to reduce the very masculinizing parts of the face to

37:54

make the face appear more feminized.

37:57

The most studied anthropomorphically is

38:01

from various studies, that it's the middle third of the glabellar

38:05

prominence right between the eyebrows.

38:08

That frontal ridge tends to be very masculinizing, and so the main goal is often to

38:12

just reduce that, and patients

38:15

can have a much more feminized appearance.

38:17

So here's an example of someone who had undergone

38:20

facial feminization with frontal reduction, and you can see there are these various

38:23

angles that help the surgeon to achieve their operative goal or the

38:27

ideal reduction for that patient.

38:30

And you can see what the frontal sinuses may look like if they have to enter them

38:34

for that surgery. Here's an example of someone who did a frontal sinus setback.

38:38

Again, they may have

38:40

bone grafting material to close the sinus or osteosynthesis plates.

38:45

Here's an example where they thought there was infection in the frontal sinus and

38:48

in the

38:50

bone graft there, but it was just some basic sinusitis related

38:54

to the surgery.

38:56

Midface feminization, so augmentation of the cheeks and cheekbones.

38:59

This can be done with soft tissue fillers, as you see in both the CT and MRI

39:03

here. So if you see that incidentally, just understand that's probably what was

39:06

going on there. You can place implants.

39:09

There are malar implants or silicone implants that can be placed.

39:12

This middle image shows one where they thought there might've been an infection in

39:15

the left implant because it had lifted, and so it showed that it just

39:19

had come undone, and they needed to replace it.

39:23

We may do preoperative 3D printing with our CT data to

39:27

help guide custom implant formation and placement.

39:31

So, I know this is at lunch, so I apologize for the surgical image there,

39:34

but I'm just showing that you can do custom face implants, as in this one.

39:39

Lower face feminization, again, changing the angle of the jaw

39:43

and making it a more feminized approach, kind of a more pointy chin rather than

39:47

a squared-off masculine chin by various

39:50

means.

39:53

Excuse me. So what's the risk of stroke from hormones?

39:55

We talked about thromboembolic phenomenon.

39:57

There is a slightly increased risk of stroke among persons receiving estrogens.

40:02

And the highest risk, again, is those same oral ethinylestradiol, the

40:06

non-bioequivalent

40:08

estrogens, smoking, and other cardiovascular risk factors.

40:11

I have two examples of stroke in trans women.

40:15

Unfortunately, both were in the lateral medulla, as in this case.

40:18

But keep that in mind that these patients may be at high risk, especially if

40:21

they're not getting monitored or if they're super physiologic on their dosing, as

40:25

were both of the cases that I have. So again, this is all from that Kaiser study

40:29

as well, that they showed increased risk of stroke.

40:32

You may have hormone-responsive tumors.

40:34

Both prolactinomas and meningiomas are under the influence of hormones, and so you

40:38

may see these incidentally. And if they're growing, you might just reduce the

40:41

hormone dosing to help reduce the size of these tumors as

40:45

appropriate.

40:47

All right, next patient.

40:49

How am I doing on time? Getting along there.

40:52

So trans woman received feminizing hormones for six years, breast augmentation for

40:56

eight, or eight years prior with silicone injections.

41:00

Vaginoplasty two weeks prior and coming with pelvic pain and fever.

41:03

Mother and sister with breast cancer. She is a police officer.

41:08

So vaginoplasty

41:11

is the

41:14

creation of a functionally acceptable neovagina.

41:17

There are various ways to do this. The most widely studied and performed is the

41:21

penoscrotal inversion vaginoplasty, which is depicted in the upper image,

41:24

where there's blunt dissection of the retroprosthetic space.

41:27

The penile skin, I'll discuss here in a little bit, is inverted, and so they have a

41:31

skin-lined neovagina.

41:34

And then an option for usually revision is the intestinal interposition, which

41:38

can be a pedicled flap of small bowel or colon

41:42

to the perineum.

41:44

So with the penoscrotal inversion vaginoplasty, the penis is disassembled.

41:48

You can see the blue marks is where they make their incisions.

41:51

They will remove as much cavernous tissue as possible, so that's the erectile

41:55

tissue.

41:56

They preserve the penile skin shaft.

41:59

They do orchiectomy at this time. They will reduce the length of the urethra.

42:04

And then with the glans and dorsal neurovascular bundle,

42:08

here they will reduce the size of the glans to create the neoclitoris, and this

42:12

will remain intact sensate-wise, so patients can actually have sexual

42:16

satisfaction from this. And then they will

42:20

do urethplasty and bring it right underneath the clitoris there.

42:24

And you can see this tube from the skin-lined neovagina there.

42:28

And they'll use the scrotal skin to produce the neolabia.

42:32

So imaging wise, it can be difficult to assess this area on

42:36

CTs, as it's usually collapsed down.

42:38

Here's an example of some MRI where it's collapsed down.

42:41

Often patients have dilators after this surgery to keep the

42:45

patency of the neovagina, and so they'll have these dilator instruments.

42:47

So if you're specifically interpreting something

42:51

for

42:53

evaluation of the neovagina, you might ask them to bring their dilator instruments.

42:56

Just make sure there's no metal components in those.

42:59

Otherwise, you can do

43:01

water sensitive gel material to look for fistulas, for

43:05

example. These are some measurements postoperatively

43:09

that have been compared to cisgender women

43:11

to basically measure how close are we achieving

43:16

anatomical results with what would be expected for cis women.

43:19

And these

43:20

have implications for sexual satisfaction and function of the neovagina after

43:24

surgery. So surgeons may request these, and this available in this

43:27

article. Complications, as you would expect, early

43:31

post-op complications with hemorrhage and infection are kind of the ones that you

43:35

worry about first. And then kind of

43:40

longer term ones, including vaginal stenosis,

43:43

rectovaginal fistula example. Here's an example of just

43:47

several pelvic abscesses after surgery.

43:50

And again, it's highly variable. This is one on T2 MRI where you have

43:54

residual T2 of high signal, and that's all the erectile tissue that's left

43:57

behind. So with sexual stimulation, that can engorge and be

44:01

uncomfortable for patients. And it can also be a source of hemorrhage.

44:05

This patient had a Mons abscess, and when they do the

44:10

glans positioning for the neoclitoris, they place that dorsal neurovascular

44:14

bundle up here. So you can imagine how painful this must've been for the patient,

44:18

who unfortunately also developed a fistula to her neovagina.

44:24

So here's enhancing residual tissue.

44:26

You can see there's just a little bit here on the left image.

44:29

Whereas on the right, there's much more cavernous tissue that was left behind.

44:34

Here's an example of a retro neovaginal fistula with

44:38

barium enema, so abnormal connection with the neovagina seen here, and

44:42

then they later scan the patient with CT, and it helps the surgeons to

44:45

delineate that defect and plan their surgery.

44:50

Chronic complication can be neovaginal prolapse or

44:54

there's a lot of work done in the pelvic floor.

44:57

So pelvic floor weakening can lead to this prolapse.

44:59

And this was a dynamic MRI that showed that it was a fixed defect and quite large,

45:03

so it had to be repaired.

45:06

All right. Final patient here is Andrew, a trans man, presented with groin

45:09

pain and cold penis after a 12-hour car ride.

45:13

He had received testosterone injections monthly.

45:15

He had had chest masculinization, phalloplasty, and scrotoplasty two years prior,

45:19

and he's a professional snowboarder.

45:22

So

45:26

phalloplasty is creation of a neophallus, and

45:30

whether it's from a phalloplasty techniques or you can do metoidioplasty as another

45:33

option. The most widely studied is this radial forearm free flap, where a

45:38

donor tissue site from the dorsal forearm is brought down

45:42

and anastomosed to the groin. And so they'll take with them

45:46

the neurovascular structures of the skin.

45:50

They'll do skin grafting to close that donor site.

45:53

But they will roll that skin donor flap into a

45:57

tube-in-tube configuration. So it's a skin-lined neourethra.

46:01

And then it's got some level of bulk to it.

46:03

So they will then reanastomose the vessels,

46:07

usually with the inferior epigastric arteries down in the groin.

46:11

And then they will also do microsurgery to reanastomose the nerve endings,

46:15

so you can actually have a tactile and sensile neophallus.

46:19

You can also do just a pedicle flap from the thigh, and so that's one option.

46:23

And you may see those changes on a CT where the donor

46:26

site looks altogether different than the contralateral thigh.

46:31

Metoidioplasty is a little different, actually has fewer complications

46:36

than the other surgery, but basically a neophallus is created from

46:40

hormonally hypertrophied clitoris.

46:41

So under the influence of testosterone, the clitoris will hypertrophy and

46:45

grow. And some up to six centimeters have been

46:49

reported. So they'll take advantage of that fact

46:52

and go ahead and perform this surgery.

46:56

The downsides is often patients can't get as much length as the other phalloplasty

47:00

procedures. But sometimes this is all the patient really needs, but it does allow

47:03

them

47:05

to have upright micturition and natural erections.

47:08

And it's a much less complicated surgery.

47:12

Here's an example of that, a hypertrophied clitoris here, and then you can see

47:15

the homologous erectile tissue is maintained so they can actually achieve

47:19

erections.

47:21

And then, let's see. You may do a CTA if you're

47:25

planning for contralateral thigh phalloplasty for looking at the

47:29

graft or the potential graft or donor site.

47:34

Post-op,

47:35

the urethrogram is going to be the gold standard for evaluating their urethra.

47:39

Again, most complications are related to their urethra or the blood supply to

47:42

these phalloplasties. And so,

47:45

there's the pendulous or the phalloplasty urethra that's been created and brought

47:49

down as we showed. Then there's this mid portion, usually from buccal

47:53

or vaginal skin grafting, that they will connect that to the native urethra

47:57

posteriorly. So you can see that these sites where there's

48:00

tenuous blood supply is where we tend to have the complications.

48:05

And again, here's an example of one where you have stenosis at this

48:08

juncture that led to dehiscence and leak

48:12

posteriorly. So, they're getting retrograde urethrograms frequently.

48:16

There's some great publications on this, in the expected imaging of it

48:21

In this case, it was just a simple growing hematoma, but they were worried about

48:24

the patency of the supplying artery.

48:27

So you can see that it was patent on this CTA.

48:31

Back to our patient. So he showed up with a cold penis.

48:34

A long car ride, and they did a Doppler ultrasound showing that the anastomotic

48:37

artery is thrombosed. They tried to clear it with

48:41

interventional radiology, unfortunately not soon enough, as he developed

48:45

necrosis in the distance from that ischemic event.

48:50

Some patients elect to get implants and erectile devices.

48:53

They look just like any other erectile implant device that we might see with

48:56

cisgender men. Differences, they may have complications more frequently

49:00

because it doesn't have a fibrous tunica to sit in.

49:04

It's in that phalloplasty tissue, which may be more at

49:08

risk for

49:10

rupture and breakdown.

49:13

Here's one example that's unfortunately, the patient developed infection around all

49:16

of the erectile implant

49:19

device components, and so this is all abscess, and it needed to be removed.

49:23

They allowed the infection to cool down before they did a revision.

49:28

So looking globally at how we improve this approach.

49:32

One is all the things I mentioned and the ways that we can improve our

49:36

approach to the patients in the department.

49:38

So they're listed here, but keep in mind, this patient population may

49:42

require a little more effort or emphasis on gender

49:46

identification and pronoun use.

49:52

Always remember that these can be invasive exams, they can be traumatic exams, as

49:55

we showed,

49:56

and so allow the patient to have autonomy at the site of the imaging.

50:02

Excuse me.

50:04

If your department cares for these patients, make sure that patients know

50:08

about it. This is an example where they studied all the breast imaging facilities

50:12

in the United States and showed that overall, many were not ready.

50:16

And this is an older publication, but I'm sure that's improved since then.

50:19

But many were not ready to provide adequate care for transgender folks.

50:24

Here's one where they looked at Google webpages and website searches

50:27

for radiology departments and transgender

50:31

experts or care there. And even in high volume centers like in

50:35

New York and San Francisco, there was no mention of transgender care in these

50:38

radiology department websites at this time.

50:42

I encourage a multidisciplinary approach.

50:44

Work with your referring clinicians, work with patients,

50:48

to ensure that the radiology department is ready to receive these patients in a

50:52

meaningful and supportive way.

50:55

Again, I always encourage community feedback, so make sure you're having

50:59

patients as part of this discussion so that you can really tailor it to the needs

51:02

of the community.

51:05

We have a multidisciplinary transgender health clinic here.

51:08

I sit on that panel from a radiology perspective, so I'm in the

51:12

background on Zoom in this image, but we do have multidisciplinary care.

51:16

But include yourself in those populations.

51:18

So reach out to your trans health center if you have one,

51:21

and ask if you can be part of that team.

51:23

And I think you'll find that everyone's very welcome to having a radiologist

51:27

to support them.

51:30

Excuse me.

51:33

Again, most importantly, listen to the community, listen to the patients.

51:35

These are more quotes from our survey.

51:38

They'll tell you where we could improve or where we're doing well.

51:42

So keep that in mind.

51:45

At this point, I will conclude and take any questions.

51:52

Thank you so much for this presentation, Dr Stoll. That was great.

51:56

We will open the floor for some questions, and we've got a couple in the Q&A box.

51:59

I don't know if you're able to see that on your Zoom.

52:02

If not, I can read

52:06

them.

52:09

Let's see.

52:11

Should be a quote bubble with a question mark in it.

52:14

I see a webinar chat.

52:17

Not that one.

52:20

Do you have a more

52:22

option?

52:23

Got it.

52:23

Awesome.

52:24

All right. So

52:29

excuse my coughing. I developed laryngitis over the weekend.

52:31

So how do we report about uterus, ovaries, prostate, and

52:35

seminal vesicles in ultrasound or CT if they are visualized in someone who's

52:38

transgender?

52:41

So the question to me seems like how to be sensitive to very

52:45

gendered anatomy related to what the

52:48

patient may see in their reports, if that's correct.

52:53

That's a question that comes up frequently.

52:56

What I have always encouraged and what I think in general the consensus

53:00

is among experts is be objective, say what you're

53:03

seeing,

53:05

because it's still the anatomy, right?

53:07

Often, these patients know what tissue they have, right?

53:10

And

53:11

certain individuals may be more dysphoric about discussing it or seeing it

53:14

reported.

53:16

But I think as long as you're not leaning on gender, like using male, female,

53:20

and really just reporting objectively, this is prostate tissue.

53:24

We have to stay objective, right?

53:28

And so that's one way. Another option is if

53:32

there is a patient that's very sensitive to that and doesn't want that sort of

53:35

information in their report,

53:38

there are ways to describe around it.

53:40

You can issue patient-friendly reports and then the separate report

53:44

for the clinician, for example. It takes that

53:48

crosstalk to understand ahead of time

53:51

how we can do things.

53:54

One thing that I tend to do is if I think someone's going to be sensitive to the

53:58

report information,

53:59

for example, on a CT abdomen and pelvis, I'll often say,

54:03

"No pelvic mass," and just avoid the mention of a

54:07

uterus and ovaries, but I'll still obviously evaluate it.

54:11

That's one way, but again,

54:13

there are different ways you can do it, and it's going to be patient specific.

54:16

Overall, I've found that most patients are totally understanding of the anatomy

54:20

that they have. Often, they don't want it anymore, and so they're often

54:24

coming to see us to get rid of it, right?

54:26

So-

54:27

And so I think just be objective, and that's the tissue that you see, right?

54:32

That's probably the best approach.

54:37

Can I go over the anatomy and point out the pelvic floor defect?

54:42

Excuse me.

54:43

I did show two sagittal images, one on CT, one on dynamic

54:47

MRI. Again, the

54:50

blunt dissection goes in the retroprostatic space through the peritenium,

54:54

and this was a chronic defect where the patient had fullness.

54:58

I only have those two images to show, so I can't scroll and really go through the

55:01

detail, but that space becomes weakened.

55:04

And that was an older

55:06

example, a case from several years ago.

55:09

And so since then, it's become the

55:13

standard of care to do

55:14

pelvic therapy with a pelvic therapist who specializes in pelvic floor

55:18

before surgery to really strengthen all those muscles to prevent this complication.

55:22

And then after the surgery, there's a lot of pelvic physiotherapy that's done

55:27

to strengthen that. So

55:28

we were able to do the dynamic MRI because that surgeon wanted to know, is this a

55:32

fixed defect or does it slide at all?

55:35

And so that was the reason for that there.

55:37

I'm sorry I don't have more detailed images to provide there.

55:44

So when I say that MRI is more sensitive than CT

55:48

for postoperative complications,

55:51

it depends what you're looking for.

55:52

So abscess, of course, CT is going to be your modality of choice with

55:56

contrast.

55:58

For most things, CT can get it.

56:01

If you're specifically looking at the nature of the

56:05

neovagina,

56:07

for example, then I think MRI is going to be better, if

56:11

you're specifically looking for that.

56:13

And I showed you the measurements and things that surgeons might like to see.

56:17

But I would wait for the postoperative period to calm down, and then maybe

56:21

six months to a year and beyond, then you can start using the MRI,

56:25

as I mentioned. It's going to be indication specific, I

56:29

think, and you would use your judgment.

56:31

The references that I left in the

56:34

presentation outline and detail that a little more.

56:38

So I would encourage you to check those out as well.

56:45

Any other question?

56:48

I think you got them all.

56:50

Okay. All right. Well, thank you again for the discussion,

56:54

for your time. I'm open to any further questions down the

56:58

road. Please just reach out.

57:00

Thank you so much for this presentation. Really appreciate it.

57:03

Thank you.

57:03

And thank you for everyone for participating in today's noon conference.

57:06

We will email out a link to this replay later today.

57:11

Be sure to join us next week on August 13th at 12:00 PM Eastern, where Dr.

57:15

Parisa Kaviani will deliver a lecture entitled "AI-Generated Radiology

57:18

Impressions." You can register for that at medality.com, and follow us

57:22

on social media for updates on future noon conferences.

57:26

Thanks again for learning with us, and have a great day.

Report

Faculty

Justin T Stowell, MD

Assistant Professor of Radiology

Mayo Clinic in Florida

Tags

Chest